Activity of sertraline against Cryptococcus neoformans: In vitro and in vivo assays

Medical Mycology

Volumn 54, Issue 3, 2016, Pages 280-286

  Trevinõ Rangel, Rogelio De J ^a   Villanueva Lozano, Hiram ^b   Hernández Rodríguez, Pedro ^b   Martínez Reséndez, Michel F ^b   Garciá Juárez, Jaime ^a   Rodríguez Rocha, Humberto ^a   González, Gloria M ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

antifungal efficacy study; antifungal in vitro susceptibility; cryptococcal meningoencephalitis; Cryptococcus neoformans; sertraline

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; SERTRALINE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIUM ISOLATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG EFFICACY; EXPERIMENTAL INFECTION; FUNGAL STRAIN; GROWTH INHIBITION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MENINGOENCEPHALITIS; MOUSE; MURINE MODEL; NONHUMAN; ANIMAL; ANIMAL STRUCTURES; BACTERIAL COUNT; COMPARATIVE STUDY; CRYPTOCOCCOSIS; CYTOCHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FUNGEMIA; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ANIMAL STRUCTURES; ANIMALS; ANTIFUNGAL AGENTS; COLONY COUNT, MICROBIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; FUNGEMIA; HISTOCYTOCHEMISTRY; HUMANS; MALE; MICE; SERTRALINE; TREATMENT OUTCOME;

EID: 84964411147     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myv109     Document Type: Article

References (31)

1. Park BJ, Wannemuehler KA, Marston BJ et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-530.
2. Ramrez-Crescencio MA, Vel ásquez-Pérez L, Raḿrez-Crescencio MA et al. Epidemiology and trend of neurological diseases associated to HIV/AIDS. Experience of Mexican patients 1995-2009. Clin Neurol Neurosurg 2013; 115: 1322-1325.
3. Saag MS, Graybill JR, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710-718.
4. Perfect JR,DismukesWE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 291-322.
5. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002; 41: 1247-1266.
6. Nayak R XJ. Effects of sertraline hydrochloride and fluconazole combinations on Cryptococcus neoformans and Cryptococcus gattii. Mycology 2010; 1: 99-105.
7. Zhai B, Wu C, Wang L et al. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother 2012; 56: 3758-3766.
8. Lass-Florl C, Dierich MP, Fuchs D et al. Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clin Infect Dis 2001; 33: E135-136.
9. Lass-Florl C, Dierich MP, Fuchs D et al. Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother 2001; 48: 775-779.
10. Gonź alez GM, Casillas-Vega N, Garza-Gonź alez E et al. Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from NortheastMexico. Folia Microbiol (Praha). 2015.
11. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 3rd. edn. Approved standard M27-A3.Wayne, PA: CLSI, 2008.
12. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-2167.
13. Larsen RA, BauerM, ThomasAMet al. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother 2004; 48: 985-991.
14. Kirkpatrick WR, Najvar LK, Bocanegra R et al. New guinea pig model of Cryptococcal meningitis. Antimicrob Agents Chemother 2007; 51: 3011-3013.
15. Thompson GR, 3rd Wiederhold NP, Najvar LK et al. A murine model of Cryptococcus gattii meningoencephalitis. J Antimicrob Chemother 2012; 67: 1432-1438.
16. Wiederhold NP, Najvar LK, Bocanegra R et al. Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Antimicrob Agents Chemother 2013; 57: 745-750.
17. Ito-Kuwa S, Nakamura K, Aoki S et al. Serotype identification of Cryptococcus neoformans by multiplex PCR. Mycoses 2007; 50: 277-281.
18. Meyer W, Aanensen DM, Boekhout T et al. Consensus multilocus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 2009; 47: 561-570.
19. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11-28.
20. Pfaller MA, Messer SA, Jones RN et al. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). J Antibiot (Tokyo) 2015; 68: 556-561.
21. Pfaller MA, Rhomberg PR, Messer SA et al. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis 2015; 82: 303-313.
22. Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006; 20: 507-544, v-vi.
23. Olivares LR,Martnez KM, Cruz RMet al. Genotyping ofMexican Cryptococcus neoformans and C. gattii isolates by PCRfingerprinting. Med Mycol 2009; 47: 713-721.
24. Orni-Wasserlauf R, Izkhakov E, Siegman-Igra Y et al. Fluconazole-resistant Cryptococcus neoformans isolated from an immunocompetent patient without prior exposure to fluconazole. Clin Infect Dis 1999; 29: 1592-1593.
25. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and-resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 1998; 42: 471-472.
26. Letendre SL, Marquie-Beck J, Ellis RJ et al. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol. 2007; 2: 120-127.
27. Winek CL, Wahba WW, Winek CL, Jr. et al. Drug and chemical blood-level data 2001. Forensic Sci Int 2001; 122: 107-123.
28. Tremaine LM, Welch WM, Ronfeld RA. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab Dispos 1989; 17: 542-550.
29. Rapaport MH, Wolkow R, Rubin A et al. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001; 104: 289-298.
30. Capilla J, Clemons KV, Stevens DA. Animal models: an important tool in mycology. Med Mycol 2007; 45: 657-684.
31. Spitzer M, Griffiths E, Blakely KM et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol 2011; 7: 499.